SARS-CoV-2 - Colchicine - Therapeutic Candidates

SARS-CoV-2 - Colchicine - Therapeutic Candidates


Colchicine is an anti-inflammatory drug used in rheumatology and particularly for the treatment of gouty arthritis or gout. Colchicine is also used in the treatment of other pathologies such as chronic atrophic polychondritis or acute pericarditis after failure of aspirin. 
Studies have shown that SARS-CoVs activate NLRP3 inflammasomes, intracytoplasmic particles that stimulate the release of pro-inflammatory cytokines. In particular, colchicine is believed to inhibit the assembly of the NLRP3 inflammasome and thus the release of cytokines, in particular interleukin-1 beta and interleukin-6. Colchicine is believed to inhibit certain functions of the inflammasome, a component of the immune system that plays a role in triggering cytokine shock and the associated inflammatory cascade. Targeting the inflammatory response with colchicine may therefore reduce complications related to Covid-19 in adults at risk or with signs of inflammatory storm. Three studies are currently underway to investigate the effects of colchicine on Covid-19, the largest, called COLCORONA, involves 6000 patients in Canada.

Cat#
Description
Size
Price Excl. VAT
C2026-100ML
 100ML 
271240-2mg
 2mg 
C640003-10mg
 10mg 
271241-10mg
 10mg 
C640003-1mg
 1mg 
271241-25mg
 25mg 
C640006-50mg
 50mg 
C7507-25g
 25g 
A3324-1g
 1g 
1519-1000
 1g 
2213-5
 5mg 
2213-25
 25mg 
C7507-02-1mg
 1mg 
C7507-03-1mg
 1mg 
C7507-04-5mg
 5mg 
271252-10mg
 10mg 
C7507-05-5mg
 5mg 
C226-500MG
 500MG 
Number of results per page : 10 50 250